Waters Corporation has announced the launch of BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, which enable precise titer measurements.
This launch is the first affinity chromatography pillar that Waters has brought to market. This is a groundbreaking step as the company continues to bring new products to market that address the unmet need in the separation of large molecules. The new pillars enable earlier access to results in upstream bioprocessing, faster method optimisation in downstream biologics development, and a new level of flexibility in the discovery, optimization and manufacturing of antibody-based drugs.
One of the biggest bottlenecks in the development of biotherapeutics such as monoclonal antibodies is the time it takes to identify and optimize a suitable cell line for antibody production," said Dr Udit Batra, President and Chief Executive Officer of Waters Corporation. "We solved this problem by developing a novel, highly efficient particle with an immobilized protein A surface and combining it with the MaxPeak Premier hardware, resulting in the most sensitive protein A column on the market."
BioResolve Protein A Affinity Columns are designed to deliver up to 7x improvement in sensitivity compared to the market leader. The novel, non-porous 3.5 μm particles enable accurate quantification of antibody titers at lower concentrations and with fewer samples. In addition, the columns have been designed to be coupled with size exclusion chromatography columns to measure titer concentrations and aggregate analysis in a single run on any LC system.
